Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 15/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.41 |
| ▸ | WNT1 | P04628 | 10/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381685 | 0.85 | GSK3B (0.56) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL20945222 | 0.85 | GSK3B (0.56) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL25424298 | 0.79 | ABL1 (0.56) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL30695432 | 0.78 | GSK3B (0.47) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL30695445 | 0.78 | DYRK1A (0.45) | PDPK1GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL30695495 | 0.77 | PIK3CD (0.55) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL20916079 | 0.72 | GSK3B (0.50) | GSK3BDYRK1AWNT1ABL1CLK2 | |
| SCHEMBL559016 | 0.71 | GSK3B (0.53) | GSK3BDYRK1AWNT1TTK | |
| SCHEMBL558380 | 0.69 | MAP3K5 (0.47) | PDPK1GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL25304732 | 0.69 | CYP11B2 (0.60) | PDPK1GSK3BDYRK1AABL1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | PDPK1 1031/4885GSK3B 685/4885DYRK1A 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.